Prolong TM, a New Revolutionary First Line Treatment for Premature Ejaculation is Licensed in Europe
LONDON, December 7, 2012 /PRNewswire/ --
Prolong TM a revolutionary new treatment for premature ejaculation (PE), was peer reviewed and presented today at the European Society for Sexual Medicine (ESSM) annual conference in Amsterdam where it was recommended as first line treatment for premature ejaculation.
During independent clinical trials in two London Teaching Hospitals the Prolong TM training programme was shown to be three times more effective and worked in 50% more men than psychosexual therapy, (the then current gold standard treatment), and is at least four to five times cheaper. The Prolong TM programme was not associated with any side effects during trials.
Men with premature or early ejaculation were found to be more sensitive to penile stimulation than those without. Dr Andy Zamar, the creator of Prolong TM explained to delegates how Prolong TM works by repeated subthreshold stimulation of the most sensitive parts of the penis producing a long term reduction of this sensitivity. This effect is called habituation and is thought to be permanent.
Men who used the Prolong TM prototype with the programme in the clinical trials improved by week one and reached maximal improvement by week six. The Prolong TM programme trained men to last on average 11 times longer during intercourse by learning to control their climax. The 11 fold improvement was maintained when they were reviewed three months after they completed the programme. The Prolong TM programme was associated with increased interest, initiative, frequency and satisfaction in intercourse.
Dr Zamar explains: "I wanted to design a programme to treat premature ejaculation w